02:50:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipum är ett biofarmaceutiskt bolag specialiserat på utveckling av ny behandling för kroniska inflammatoriska sjukdomar. Läkemedelskandidaten SOL-116 är en humaniserad antikropp som blockerar en tidigare förbisedd målmolekyl (BSSL) i immunförsvaret. Bolaget är i första hand inriktade på den sällsynta sjukdomen barnreumatism samt ledgångsreumatism, men utvärderar även en rad andra inflammatoriska sjukdomar. Lipum har sin verksamhet i Umeå.

Kalender

2023-03-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-10-12 Extra Bolagsstämma 2022
2022-07-27 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Ordinarie utdelning LIPUM 0.00 SEK
2022-04-26 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-11-01 08:30:00
Press release: Umeå, November 1, 2021. Lipum (publ) is proceeding towards start of clinical trials according to plan. Dr. Maria Wanderoy now joins as Project Director to head the drug development of SOL-116.

With an ongoing program including toxicology- and safety studies, as well as GMP manufacturing of the drug candidate SOL-116, Lipum is in a late pre-clinical stage and planning for start of clinical trials during 2022. Maria Wanderoy has now taken the role as Project Director to head the drug development.

Maria Wanderoy holds a PhD in neurochemistry and neurotoxicology from Stockholm University in Sweden and she brings more than 25 years’ experience from the pharmaceutical industry. She has held positions ranging from global-, clinical- and preclinical project manager to senior research scientist. Maria has, thus, a broad understanding and experience of the drug development process all the way from early discovery to planning and execution of clinical programs. She has also several years of experience as lead project manager for medical device development projects, for example, autoinjectors used in the administration of medicinal products to patients.

"I am very enthusiastic for the experience that Maria brings and that she takes a leader role for Lipum's competent team. This is a great step towards a successful clinical development phase for the company.” - says Einar Pontén, CEO.

For further information, please contact: 

Einar Pontén, CEO
E-post:            
einar.ponten@lipum.se
Mobile:              +46 70 578 34 95
Web:               
www.lipum.se

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.